Bernd O. Wetzel

DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany.

Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria.

Gruner Böhringer AG engages in the provision of engineering and planning services. It specializes in the areas of infrastructure construction, hydraulic and sanitary engineering, geomatics, geology, and geographic information systems. The company was founded in 1952 and is headquartered in Oberwil, Switzerland.

Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany.